# Axogen Q3 2026 Earnings Report Highlights

> Axogen reports 26.2% revenue growth with $75.8 million Q3 revenue, $200 million BioCircuit acquisition, and prostate nerve reconstruction plans.
- Title: Axogen Q3 2026 Earnings Report Highlights · The Motley Fool
- Summary: Axogen reports 26.2% revenue growth with $75.8 million Q3 revenue, $200 million BioCircuit acquisition, and prostate nerve reconstruction plans. Axogen…
- Keywords: axogen, q3 2026, revenue growth, bio circuit, prostate nerve reconstruction, nerve tape, avance nerve graft, breast reconstruction, extremities, omf, finance, money
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/10/28/axogen-axgn-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-10-28T18:08:00+00:00
- Read time: 2 min
- Topics: axogen, q3 2026, revenue growth, bio circuit, prostate nerve reconstruction, nerve tape, avance nerve graft, breast reconstruction, extremities, omf, finance, money
## Q3 Revenue Growth
Axogen reported $75.8 million in Q3 2026 revenue, a 26.2% year-over-year increase driven by strong unit volume demand for Avance Nerve Graft.
## BioCircuit Acquisition
Axogen completed a $200 million cash purchase of BioCircuit Technologies on Oct. 1, 2026, integrating NerveTape into its direct sales platform.
## Prostate Nerve Reconstruction
Axogen plans to initiate prostate nerve reconstruction market development in 2027 with clinical data showing 80% erectile function recovery and 95% urinary continence.
## Breast Market Penetration
Breast reconstruction segment grew 60% year-over-year with 485 active accounts and 590 active surgeons, representing 11% market penetration.
## NerveTape Integration
NerveTape is positioned as a faster, easier coaptation aid for direct nerve repair procedures, potentially replacing microsuturing in 40% to 50% of cases.
## Payer Coverage Expansion
96% of U.S. covered lives now have access to Avance following additions of 87.6 million commercial and Medicare Advantage lives across major payers.
## Clinical Outcomes
80% of prostate patients achieved erectile function recovery defined as SHIM score of 15 or higher at six months post-operation.
## 2027 Revenue Guidance
Axogen raised full-year 2026 revenue guidance to at least $290 million, including $7 million from BioCircuit, representing 29% projected growth.
## Gross Margin Impact
The step-up in value of acquired BioCircuit inventory could negatively impact gross margin in Q4 and full year relative to current expectations.
## Nerve-RESTORE Study
Nerve-RESTORE study enrolled first patient in randomized comparison of Avance Nerve Graft and sural nerve autograft for mixed and motor nerve repair.
## EMBRACE Study
EMBRACE study start-up underway to evaluate sensory recovery in breast reconstruction with first site initiation planned for Q4.
## MATCH Study Results
MATCH study demonstrated motor recovery with Avance was comparable to nerve autograft in mixed and motor nerve reconstruction.
## Free Cash Flow
Axogen generated $18.9 million free cash flow through first nine months of 2026, compared to a loss of $5.9 million in prior year period.
## 2027 NerveTape Projection
Axogen projects $34 million in incremental NerveTape sales for 2027, net of potential internal product cannibalization.
## Organic Growth Guidance
Axogen expects organic revenue growth of at least 26% for 2026, excluding BioCircuit contribution.
## Prostate Clinical Data
220 patients across 15 sites received prostate nerve reconstruction with Avance, showing 80% erectile function recovery and 95% urinary continence.
## Key takeaway

Axogen achieved 26.2% Q3 revenue growth to $75.8 million, completed $200 million BioCircuit acquisition, and plans prostate nerve reconstruction market development in 2027.